Publications scientifiques sur les diagnostics non invasifs BioPredictive
Études évaluées par les pairs validant les diagnostics sanguins BioPredictive pour les maladies du foie — des cohortes pionnières aux méta-analyses à long terme.
138/435
Résultats pour
“randomized trial”
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
…12-month, randomized, double-blind, placebo-controlled multicenter trial to evaluate the…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
…using the data of a randomized trial of combination peginterferon alfa-2b…
-
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. Key publication
…in patients included in a randomized trial of interferon (IFN) using repeated…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
…NashTest and FibroTest) through three randomized sham controlled studies. ### Methods The FibroMax…
-
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
…fibrosis score > or = 2 were randomized to receive peginterferon alpha-2a 180…
-
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
### Background And Aims Primary prevention of variceal bleeding with beta-blockers improves…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
…NASH in this 6-month randomized, double-blind, placebo-controlled study. ### Method…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
…EPIC(3) included a prospective trial assessing long-term peginterferon alfa-2b…
-
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.
SUMMARY: BACKGROUND: Recent studies strongly suggest that due to the limitations and…
-
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication
…Patients with chronic hepatitis B (HBeAg+ and HBeAg-) randomized in two trials…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.
…1980 to 2010 searching for randomized controlled trials and observational studies on…
-
Noninvasive prediction of fibrosis in patients with chronic hepatitis C.
-
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication
### Background The area under the ROC curve (AUC) is widely used as…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease. Key publication Meta Analysis
### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
### Background Few data are available on chronic hepatitis C (CHC) in elderly…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
…Patients with chronic HCV were randomized to receive interferon-based therapy for…
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
Liver fibrosis is a common pathway leading to cirrhosis, which is the…
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
### Background Our aim was to assess the natural history of liver fibrosis…
-
Biomarkers of liver fibrosis. Review
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis
### Background Liver biopsy and virological end points are standard references for assessing…
-
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Meta Analysis
### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…
-
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
### Unlabelled To optimize the management of patients with chronic hepatitis C virus…
-
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
In therapy with standard interferon and ribavirin, five independent risk factors (RF…
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to…
-
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis
FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
**Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…
-
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
### Objectives To compare plasma antiretroviral concentrations in HIV-HCV co-infected and…
-
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
### Objectives The noninvasive serum markers, FibroTest-ActiTest (FT-AT), are an alternative…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…
-
Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
### Aim To assess the diagnostic value of Fibrotest in comparison with liver…
-
Silymarin in non alcoholic fatty liver disease.
### Aim This study was undertaken to evaluate the hepatic effects of silybum…
-
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
### Background Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for…
-
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…
-
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…
-
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Review
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication
…coronary calcification and cardiovascular risk. ### Trial Registration ClinicalTrials.gov identifiers NCT02431234 and…
-
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.
The course of hepatitis C virus (HCV) infection carriers with normal/near…
-
Changes of non-invasive markers and FibroScan values during HCV treatment.
The recent advent of non-invasive methods for assessment of fibrosis allows…
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
### Background & Aims The aim of this study was to determine the diagnostic…
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
### Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
### Background Biopsy is the usual gold standard for liver steatosis assessment. The…
-
Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).
BACKGROUND: Biochemical marker combinations, including alpha2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl…
-
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
### Objective And Methods We assessed the reliability of non-invasive biological scoring…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
### Background & Aims Although methotrexate (MTX) is used in the effective treatment of…
-
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…
-
Diagnostic value of FibroTest with normal serum aminotransferases.
-
Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.
### Aims FibroTest and ActiTest are noninvasive tests used in determining the level…
-
[Prognosis assessment of alcoholic liver disease: how and why?]. Review
Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…
-
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
### Background/Aims To compare non-invasive biological liver fibrosis scores, as alternatives…
-
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Review
It is estimated that hepatitis C virus (HCV) infects chronically about 160…
-
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease…
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
### Background Assessment of fibrosis progression in chronic liver disease relies upon non…
-
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
### Objective Liver biopsy, the gold standard for assessing hepatitis C virus (HCV…
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
### Objectives Liver fibrosis in chronic hepatitis C is related to sex, age…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication
### Background One of the unmet needs in patients with metabolic risks is…
-
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.
### Background Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients…
-
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
### Background And Aims Transient elastography (FibroScan; Echosens, Paris, France) is a novel…
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review
### Background Chronic HCV is one of the major causes of morbidity and…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Fibromax is a diagnostic tool composed of the combination of 4 non…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.
### Background An accurate diagnosis of hepatitis C virus (HCV)-related liver lesions…
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Review
The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…
-
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…
-
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.
### Background The Fib-4 index is a simple and inexpensive biomarker to…
-
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.
We applied our 'clinical glycomics' technology, based on DNA sequencer/fragment analyzers…
-
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.
BACKGROUND: Biochemical markers for liver fibrosis (FibroTest) and necroinflammatory features (ActiTest) are…
-
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
### Background The area under the receiver operating characteristic (ROC) curve is widely…
-
Biomarkers for liver disease in urea cycle disorders.
…at risk for this complication. ### Trial Registration This study has been registered…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
### Background & Objectives One of the multiple factors contributing to virological response in…
-
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
Although most hepatitis C virus (HCV) infections are acquired by injection drug…
-
Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.
Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…
-
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Key publication
FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…
-
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication
### Background FibroTest, a noninvasive method of measuring biomarkers of liver fibrosis, is…
-
Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.
### Background Liver biopsy is an imperfect gold standard for assessing the disease…
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…
-
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.
### Background/Aims In chronic hepatitis C, biopsy is the gold standard for…
-
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.
As an alternative to liver biopsy, an index of five biochemical markers…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…
-
Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.
Transient elastography (TE) is a noninvasive technique to evaluate liver fibrosis. We…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.
Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…
-
Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.
### Background & Aims Hepatitis C virus (HCV) infection has been shown to be…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…
-
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.
Liver stiffness was measured by transient elastography (FibroScan) in 228 consecutive patients…
-
Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.
### Objectives Combination of alpha 2-macroglobulin, haptoglobin, apolipoprotein-A1, gamma-glutamyl transpeptidase…
-
FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Meta Analysis
### Background The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.
### Background Liver disease is the third leading cause of mortality in patients…
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
### Background The best technique to estimate portal hypertension (PHT) is to measure…
-
FibroMAX: towards a new universal biomarker of liver disease? Review
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Key publication
### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…
-
Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.
### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…
-
[Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest].
The follow up of patients with chronic liver diseases and the data…
-
Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
### Objectives Combining noninvasive tests increases diagnostic accuracy for staging liver fibrosis in…
-
Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.
### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…
-
Noninvasive Assessment of Liver Fibrosis. Key publication Review
-
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
### Background FibroTest has been validated for the diagnosis of liver fibrosis in…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…
-
Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.
### Background/Aims To assess prospectively the accuracy of transient elastography (TE, FibroScan…
-
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
### Background And Aim The validity of biomarkers of excessive alcohol drinking (EAD…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).
The aim of this study was to evaluate the diagnostic usefulness of…
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
### Background Blood tests of liver injury are less well validated in non…
-
Assessment of liver fibrosis: noninvasive means.
Liver biopsy, owing to its limitations and risks, is an imperfect gold…
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
### Background African Americans have lower reported likelihood of hepatitis C virus-related…
-
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
Affichage de la liste complète des résultats. La page est rendue côté serveur et non paginée.